Equities research analysts at B. Riley initiated coverage on shares of Biomerica (NASDAQ:BMRA) in a research note issued to investors on Thursday, January 4th, MarketBeat reports. The brokerage set a “buy” rating and a $7.50 price target on the stock. B. Riley’s target price indicates a potential upside of 46.20% from the company’s current price.
Separately, ValuEngine lowered shares of Biomerica from a “hold” rating to a “sell” rating in a research note on Friday, December 1st.
Biomerica (NASDAQ BMRA) traded down $0.17 during midday trading on Thursday, hitting $5.13. 402,100 shares of the stock were exchanged, compared to its average volume of 499,562. The company has a market capitalization of $43.71, a PE ratio of -39.46 and a beta of 6.22. Biomerica has a 12-month low of $1.93 and a 12-month high of $9.32.
WARNING: “Biomerica (NASDAQ:BMRA) Research Coverage Started at B. Riley” was first reported by Week Herald and is the sole property of of Week Herald. If you are viewing this news story on another site, it was illegally copied and reposted in violation of United States & international copyright legislation. The correct version of this news story can be viewed at https://weekherald.com/2018/01/12/biomerica-bmra-coverage-initiated-by-analysts-at-b-riley.html.
Biomerica, Inc is a biomedical company, which develops, manufactures and markets medical diagnostic products for the early detection and monitoring of chronic diseases and medical conditions. The Company’s medical diagnostic products are sold around the world in over two markets, including clinical laboratories and point of care (physicians’ offices and over-the-counter drugstores).
Receive News & Ratings for Biomerica Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biomerica and related companies with MarketBeat.com's FREE daily email newsletter.